{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:54:38Z","timestamp":1761540878605},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,12,2]],"date-time":"2008-12-02T00:00:00Z","timestamp":1228176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s00592-008-0079-y","type":"journal-article","created":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T17:12:28Z","timestamp":1228151548000},"page":"253-261","source":"Crossref","is-referenced-by-count":28,"title":["Diabetes, vascular complications and antiplatelet therapy: open problems"],"prefix":"10.1007","volume":"46","author":[{"given":"A. M.","family":"Cerbone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Macarone-Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Saldalamacchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"Rivellese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,2]]},"reference":[{"key":"79_CR1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1161\/01.CIR.0000089189.70578.E2","volume":"108","author":"TF Luscher","year":"2003","unstructured":"Luscher TF, Creager MA, Beckman JA, Casentino F (2003) Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy. Circulation 108:1655\u20131661","journal-title":"Circulation"},{"key":"79_CR2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J Stamler","year":"1993","unstructured":"Stamler J, Vaccaro O, Neaton JD, Wentwort D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16:434\u2013444","journal-title":"Diabetes Care"},{"issue":"5","key":"79_CR3","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/j.amjmed.2003.10.016","volume":"116","author":"RW Nesto","year":"2004","unstructured":"Nesto RW (2004) Correlation between cardiovascular disease and diabetes mellitus current concepts. Am J Med 116(5):11S\u201322S","journal-title":"Am J Med"},{"key":"79_CR4","first-page":"1","volume":"13","author":"UKPDS Group","year":"1990","unstructured":"UKPDS Group (1990) UK Prospective Diabetes Study 6: complications in newly diagnosed type II diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 13:1\u201311","journal-title":"Diabetes Res"},{"key":"79_CR5","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","volume":"287","author":"JA Beckman","year":"2002","unstructured":"Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570\u20132581","journal-title":"JAMA"},{"key":"79_CR6","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.2174\/1381612054367337","volume":"11","author":"C Watala","year":"2005","unstructured":"Watala C (2005) Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharm Des 11:2331\u20132365","journal-title":"Curr Pharm Des"},{"issue":"Suppl 2","key":"79_CR7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/diab.32.2.S14","volume":"32","author":"JA Colwell","year":"1983","unstructured":"Colwell JA, Winocour PD, Halushka PV (1983) Do platelets have anything to do with diabetic microvascular disease? Diabetes 32(Suppl 2):14\u201319","journal-title":"Diabetes"},{"key":"79_CR8","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1538-7836.2004.00836.x","volume":"2","author":"P Ferroni","year":"2004","unstructured":"Ferroni P, Basili S, Falco A, Davi G (2004) Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2:1282\u20131291","journal-title":"J Thromb Haemost"},{"key":"79_CR9","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJM199006213222503","volume":"322","author":"G Davi","year":"2001","unstructured":"Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C (2001) Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322:1769\u20131774","journal-title":"N Engl J Med"},{"key":"79_CR10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(65)91656-9","volume":"1","author":"JM Bridges","year":"1965","unstructured":"Bridges JM, Dalby AM, Millar JHD, Weaver JA (1965) An effect of d-glucose on platelet stickiness. Lancet 1:75\u201377","journal-title":"Lancet"},{"key":"79_CR11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2362.1984.tb02092.x","volume":"14","author":"A D\u2019Angelo","year":"1984","unstructured":"D\u2019Angelo A, Micossi P, Mannucci PM, Garimberti P, Franchi F, Pozza G (1984) Increased production of platelet thromboxane B2 in non-insulin-dependent diabetes: relationship to vascular complications. Eur J Clin Invest 14:83\u201386","journal-title":"Eur J Clin Invest"},{"key":"79_CR12","first-page":"42","volume":"57(Suppl)","author":"C Watala","year":"2005","unstructured":"Watala C, Boncler M, Gresner P (2005) Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 57(Suppl):42\u201358","journal-title":"Pharmacol Rep"},{"key":"79_CR13","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/0735-1097(96)00019-8","volume":"27","author":"HJ Oskarsson","year":"1996","unstructured":"Oskarsson HJ, Hofmeyer TG (1996) Platelet from diabetic patients with diabetes mellitus have impaired ability to mediate vasodilatation. J Am Coll Cardiol 27:1464\u20131470","journal-title":"J Am Coll Cardiol"},{"key":"79_CR14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1055\/s-0038-1650518","volume":"76","author":"G Davi","year":"1996","unstructured":"Davi G, Belvedere M, Vigneri S, Catalano I, Giammarresi C, Roccaforte S, Consoli A, Mezzetti A (1996) Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus. Thromb Haemost 76:34\u201337","journal-title":"Thromb Haemost"},{"key":"79_CR15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1538-7836.2005.01351.x","volume":"3","author":"AD Michelson","year":"2005","unstructured":"Michelson AD, Cattaneo M et al (2005) Aspirin-resistance: position paper of the working group on aspirin resistance. J Thromb Haemost 3:1309\u20131311","journal-title":"J Thromb Haemost"},{"key":"79_CR16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1182\/blood.V68.4.886.886","volume":"68","author":"G Di Minno","year":"1986","unstructured":"Di Minno G, Silver MJ, Cerbone AM, Murphy S (1986) Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 68:886\u2013891","journal-title":"Blood"},{"key":"79_CR17","first-page":"950","volume":"95","author":"JM Gerrard","year":"1980","unstructured":"Gerrard JM, Stuart MJ, Rao GHR, Steffes MW, Mauer SM, Brown DM, White JG (1980) Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats. J Lab Clin Med 95:950\u2013958","journal-title":"J Lab Clin Med"},{"key":"79_CR18","first-page":"1","volume":"5","author":"R Jokl","year":"1997","unstructured":"Jokl R, Colwell JA (1997) Arterial thrombosis and atherosclerosis in diabetes. Diabetes Metab Rev 5:1\u201315","journal-title":"Diabetes Metab Rev"},{"key":"79_CR19","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/diacare.26.7.2181","volume":"26","author":"JA Colwell","year":"2003","unstructured":"Colwell JA, Nesto RW (2003) The platelets in diabetes. Diabetes Care 26:2181\u20132188","journal-title":"Diabetes Care"},{"key":"79_CR20","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.1992.03490100090033","volume":"268","author":"ETDRS Investigators","year":"1992","unstructured":"ETDRS Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. J Am Med Assoc 268:1292\u20131300","journal-title":"J Am Med Assoc"},{"key":"79_CR21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","volume":"308","author":"Antiplatelet trialists\u2019 Collaboration","year":"1994","unstructured":"Antiplatelet trialists\u2019 Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various category of patients. Br Med J 308:81\u2013106","journal-title":"Br Med J"},{"key":"79_CR22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialist\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialist\u2019 Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br Med J 324:71\u201386","journal-title":"Br Med J"},{"key":"79_CR23","first-page":"349","volume":"2","author":"ISIS 2","year":"1988","unstructured":"ISIS 2 (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS\u20132. ISIS-2 (Second International Study Of Infarct Survival) collaborative group. Lancet 2:349\u2013360","journal-title":"Lancet"},{"key":"79_CR24","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2337\/diacare.20.11.1767","volume":"20","author":"JA Colwell","year":"1997","unstructured":"Colwell JA (1997) Aspirin therapy in diabetes. Diabetes Care 20:1767\u20131771","journal-title":"Diabetes Care"},{"key":"79_CR25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","volume":"321","author":"Steering Committee of the Physicians\u2019 Health Study Research Group","year":"1989","unstructured":"Steering Committee of the Physicians\u2019 Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physicians\u2019 Health Study. N Engl J Med 321:129\u2013135","journal-title":"N Engl J Med"},{"key":"79_CR26","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S (1998) Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial: HOT study group. Lancet 351:1755\u20131762","journal-title":"Lancet"},{"key":"79_CR27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","volume":"357","author":"Collaborative group of the Primary Prevention Project","year":"2001","unstructured":"Collaborative group of the Primary Prevention Project (2001) Low dose aspirin and vit E in people at cardiovascular risk: a randomized trial in general practice. Lancet 357:89\u201395","journal-title":"Lancet"},{"key":"79_CR28","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","volume":"26","author":"M Sacco","year":"2003","unstructured":"Sacco M, Pellegrini F, Roncaglioni MC, Venzini F, Tognoli G, Nicolucci A (2003) On behalf of the PPP collaborative group primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Diabetes Care 26:3264\u20133272","journal-title":"Diabetes Care"},{"key":"79_CR29","first-page":"264","volume":"15","author":"HA Arjomand","year":"2003","unstructured":"Arjomand HA, Roukoz B, Surabhi SK, Cohen M (2003) Platelets and antiplatelet therapy in patients with diabetes mellitus. J Invasive cardiol 15:264\u2013269","journal-title":"J Invasive cardiol"},{"key":"79_CR30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2337\/dc07-9917","volume":"30","author":"JB Buse","year":"2007","unstructured":"Buse JB et al (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care 30:162\u2013172","journal-title":"Diabetes Care"},{"key":"79_CR31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.106.179294","volume":"115","author":"JB Buse","year":"2007","unstructured":"Buse JB et al (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus. Circulation 115:114\u2013126","journal-title":"Circulation"},{"key":"79_CR32","first-page":"61S","volume":"23","author":"American Diabetic Association Position Statement","year":"2000","unstructured":"American Diabetic Association Position Statement (2000) Aspirin therapy in diabetes. Diabetes Care 23:61S\u201362S","journal-title":"Diabetes Care"},{"key":"79_CR33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/01.CIR.0000020190.45892.75","volume":"106","author":"TA Pearson","year":"2002","unstructured":"Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA (2002) AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases (AHA scientific statement). Circulation 106:388\u2013391","journal-title":"Circulation"},{"key":"79_CR34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","volume":"90","author":"DL Bhatt","year":"2002","unstructured":"Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ (2002) Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 90:625\u2013628","journal-title":"Am J Cardiol"},{"key":"79_CR35","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/archopht.1990.01070130079035","volume":"108","author":"TIMAD Study Group","year":"1990","unstructured":"TIMAD Study Group (1990) Ticlopidine treatment reduces the progression of non proliferative diabetic retinopathy. Arch Ophtalmol 108:1577\u20131583","journal-title":"Arch Ophtalmol"},{"key":"79_CR36","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329\u20131339","journal-title":"Lancet"},{"key":"79_CR37","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1056\/NEJM200206063462309","volume":"346","author":"JM Gaspoz","year":"2002","unstructured":"Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Duntz KM, Hunink MG, Goldman L (2002) Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary artery disease. N Engl J Med 346:1819\u20131821","journal-title":"N Engl J Med"},{"key":"79_CR38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators","year":"2001","unstructured":"The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494\u2013502","journal-title":"N Engl J Med"},{"key":"79_CR39","unstructured":"American College of Cardiology website: ACC\/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: unstable angina\/non-ST elevation myocardial infarction. Available at http:\/\/www.acc.org . Accessed 29 Sept 2002"},{"key":"79_CR40","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/01.ATV.13.9.1346","volume":"13","author":"G Davi","year":"1993","unstructured":"Davi G, Patrono C, Catalano I, Custro N, Giammarresi C, Ganci A, Cosentino F, Notarbartolo A (1993) Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. Arterioscler Thromb 13:1346\u20131349","journal-title":"Arterioscler Thromb"},{"key":"79_CR41","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2337\/diabetes.47.3.423","volume":"47","author":"A Giustina","year":"1998","unstructured":"Giustina A, Perini P, Desenzani P, Bossoni S, Ianniello P, Milani M, Davi G, Romanelli G (1998) Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes 47:423\u2013430","journal-title":"Diabetes"},{"key":"79_CR42","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ehj.2004.07.013","volume":"25","author":"GG Neri-Serneri","year":"2004","unstructured":"Neri-Serneri GG, Coccheri S, Marubini E, Violi F (2004) For the committees and the investigators of the drug evaluation in atherosclerotic vascular disease in diabetics (DAVID) study group. Eur Heart J 25:1845\u20131852","journal-title":"Eur Heart J"},{"key":"79_CR43","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1161\/hc4801.100029","volume":"104","author":"M Roffi","year":"2001","unstructured":"Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C et al (2001) Platelet glycoprotein IIb\/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndrome. Circulation 104:2767\u20132771","journal-title":"Circulation"},{"key":"79_CR44","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0735-1097(99)00650-6","volume":"35","author":"DL Bhatt","year":"2000","unstructured":"Bhatt DL, Marso SP, Lincoff M et al (2000) Abxicimab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 35:922\u2013928","journal-title":"J Am Coll Cardiol"},{"key":"79_CR45","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.126.3_suppl.234S","volume":"126","author":"C Patrono","year":"2004","unstructured":"Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 126:234S\u2013264S","journal-title":"Chest"},{"key":"79_CR46","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","volume":"41","author":"PA Gum","year":"2003","unstructured":"Gum PA, Kottke-Marchant K, Welsh PA et al (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961\u2013965","journal-title":"J Am Coll Cardiol"},{"key":"79_CR47","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-142-5-200503010-00012","volume":"142","author":"S Sanderson","year":"2005","unstructured":"Sanderson S, Emery J, Baglin T, Kinmonth AL (2005) Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 142:370\u2013380","journal-title":"Ann Intern Med"},{"key":"79_CR48","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1111\/j.1538-7836.2005.01633.x","volume":"3","author":"FM Pulcinelli","year":"2005","unstructured":"Pulcinelli FM, Riondino S, Celestini A, Pignatelli P, Di Renzo L, Violi F (2005) Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost 3:2784\u20132789","journal-title":"J Thromb Haemost"},{"issue":"1","key":"79_CR49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.crd.0000148175.60718.69","volume":"14","author":"C Hanjis","year":"2006","unstructured":"Hanjis C, Frishman WH, Lerner RG (2006) Aspirin resistance: mechanisms and clinical implications. Cardiol Rev 14(1):18\u201325","journal-title":"Cardiol Rev"},{"key":"79_CR50","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.amjcard.2005.09.093","volume":"97","author":"SS Mehta","year":"2006","unstructured":"Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB (2006) Comparison of aspirin resistance in type I versus type 2 diabetes mellitus. Am J Cardiol 97:567\u2013570","journal-title":"Am J Cardiol"},{"key":"79_CR51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.thromres.2004.02.017","volume":"113","author":"G Di Minno","year":"2004","unstructured":"Di Minno G, Violi F (2004) Aspirin resistance and diabetic angiopathy: back to the future. Thromb Res 113:97\u201399","journal-title":"Thromb Res"},{"key":"79_CR52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2003.12.016","volume":"113","author":"C Watala","year":"2004","unstructured":"Watala C, Golanski J, Pluta J, Boncler M, rozalski M, Luzak B, Kropiwnicka A, Drzewoski J (2004) Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)\u2014its relation to metabolic control. Thromb Res 113:101\u2013113","journal-title":"Thromb Res"},{"issue":"5","key":"79_CR53","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/diacare.27.5.1245","volume":"27","author":"J Drezewoski","year":"2004","unstructured":"Drezewoski J, Watala C (2004) Is aspirin resistance a real problem in people with type 2 diabetes? Diabetes Care 27(5):1245\u20131246","journal-title":"Diabetes Care"},{"key":"79_CR54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00109-004-0600-x","volume":"83","author":"C Watala","year":"2005","unstructured":"Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, Drzewoski J (2005) Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 83:148\u2013158","journal-title":"J Mol Med"},{"key":"79_CR55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.326.7380.82","volume":"326","author":"M Friend","year":"2003","unstructured":"Friend M, Vucenik I, Miller M (2003) Research pointers: platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 326:82\u201383","journal-title":"BMJ"},{"key":"79_CR56","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1161\/01.ATV.17.11.3230","volume":"17","author":"G Davi","year":"1997","unstructured":"Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F et al (1997) In vivo formation of 8-Epi- prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 17:3230\u20133235","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"79_CR57","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0735-1097(03)00088-3","volume":"41","author":"GG Biondi-Zoccai","year":"2003","unstructured":"Biondi-Zoccai GG, Abbate A, Liuzzo G et al (2003) Atherothrombosis, inflammation and diabetes. J Am Coll Cardiol 41:1071\u20131077","journal-title":"J Am Coll Cardiol"},{"key":"79_CR58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.321.7252.13","volume":"321","author":"TW Meade","year":"2000","unstructured":"Meade TW, Brennan PJ (2000) Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 321:13\u201317","journal-title":"BMJ"},{"key":"79_CR59","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","volume":"345","author":"F Catella-Lawson","year":"2001","unstructured":"Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809\u20131817","journal-title":"N Engl J Med"},{"key":"79_CR60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","volume":"107","author":"WC Lau","year":"2003","unstructured":"Lau WC, Waskell LA, Watkins PB et al (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet activation: a new drug\u2013drug interaction. Circulation 107:32\u201337","journal-title":"Circulation"},{"issue":"4","key":"79_CR61","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4065\/81.4.518","volume":"81","author":"ED Michos","year":"2006","unstructured":"Michos ED, Ardehali R, Blumenthal RS, Lange RA, Ardehali H (2006) Aspirin and clopidogrel resistance. Mayo Clin Proc 81(4):518\u2013526","journal-title":"Mayo Clin Proc"},{"key":"79_CR62","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2005.01.034","volume":"45","author":"TA Nguyen","year":"2005","unstructured":"Nguyen TA, Diodati JG, Pharard C (2005) Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45:1157\u20131164","journal-title":"J Am Coll Cardiol"},{"key":"79_CR63","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2006.03.038","volume":"48","author":"DJ Angiolillo","year":"2006","unstructured":"Angiolillo DJ, Bernardo E, Ramirez C et al (2006) Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48:298\u2013304","journal-title":"J Am Coll Cardiol"},{"key":"79_CR64","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1111\/j.1538-7836.2006.02183.x","volume":"4","author":"D Sibbing","year":"2006","unstructured":"Sibbing D et al (2006) Diabetes mellitus and platelet function after administration of aspirin and a single 600\u00a0mg dose of clopidogrel. J Thromb Haemost 4:2566\u20132568","journal-title":"J Thromb Haemost"},{"key":"79_CR65","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.106.667741","volume":"11","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ et al (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation 11:708\u2013716","journal-title":"Circulation"},{"issue":"7","key":"79_CR66","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/00003495-200767070-00005","volume":"67","author":"S Coccheri","year":"2007","unstructured":"Coccheri S (2007) Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 67(7):997\u20131026","journal-title":"Drugs"},{"key":"79_CR67","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/archinte.160.10.1409","volume":"160","author":"T Stys","year":"2000","unstructured":"Stys T, Lawson WE, Smaldone G, Sys A (2000) Does aspirin attenuate the beneficial effects of angiotensin converting enzyme inhibition in heart failure? Arch Int Med 160:1409\u20131413","journal-title":"Arch Int Med"},{"key":"79_CR68","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/S0735-1097(99)00129-1","volume":"33","author":"J Leor","year":"1999","unstructured":"Leor J, Reicher-Reiss H, Goldbourt U, Boyko V, Gottlieb S, Battler A, Behar S (1999) Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 33:1920\u20131925","journal-title":"J Am Coll Cardiol"},{"key":"79_CR69","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.1997.00440340025002","volume":"157","author":"SF Dineen","year":"1997","unstructured":"Dineen SF, Gerstein HC (1997) The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. Arch Int Med 157:1413\u20131418","journal-title":"Arch Int Med"},{"key":"79_CR70","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1161\/01.HYP.26.6.869","volume":"26","author":"JR Sowers","year":"1995","unstructured":"Sowers JR, Epstein M (1995) Diabetes mellitus and associated hypertension, vascular disease and nephropathy. Hypertension 26:869\u2013879","journal-title":"Hypertension"},{"key":"79_CR71","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/01.ASN.0000093238.09114.40","volume":"15","author":"M Trovati","year":"2004","unstructured":"Trovati M, Cavalot F (2004) Optimization of hypolipidemic and antiplatelet treatment in the diabetic patient with renal disease. J Am Soc Nephrol 15:S12\u2013S20","journal-title":"J Am Soc Nephrol"},{"key":"79_CR72","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/ndt\/16.5.987","volume":"16","author":"S Sagedal","year":"2001","unstructured":"Sagedal S, Hartmann A, Sundstramk BjornsenS, Brosstad F (2001) Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 16:987\u2013993","journal-title":"Nephrol Dial Transplant"},{"key":"79_CR73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ajh.2830070203","volume":"7","author":"RW Steiner","year":"1979","unstructured":"Steiner RW, Coffins C, Carvalho AD (1979) Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Haematol 7:107\u2013117","journal-title":"Am J Haematol"},{"key":"79_CR74","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/0002-9343(85)90051-8","volume":"79","author":"G Di Minno","year":"1985","unstructured":"Di Minno G, Martinez J, McKean ML et al (1985) Platelet dysfunction in uremia. Am J Med 79:552\u2013559","journal-title":"Am J Med"},{"key":"79_CR75","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jcp.25.9.745","volume":"25","author":"EP Evans","year":"1972","unstructured":"Evans EP, Branch RA, Bloom AL (1972) A clinical and experimental study of platelet function in chronic renal failure. J Clin Pathol 25:745\u2013753","journal-title":"J Clin Pathol"},{"key":"79_CR76","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1055\/s-2004-835678","volume":"30","author":"P Boccardo","year":"2004","unstructured":"Boccardo P, Remuzzi G, Galbusera M (2004) Platelet dysfunction in renal failure. Semin Thromb Hemost 30:579\u2013589","journal-title":"Semin Thromb Hemost"},{"key":"79_CR77","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(86)92372-X","volume":"1","author":"M Livio","year":"1986","unstructured":"Livio M, Benigni A, Vigano G et al (1986) Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1:414\u2013416","journal-title":"Lancet"},{"key":"79_CR78","doi-asserted-by":"crossref","first-page":"555","DOI":"10.7326\/0003-4819-137-7-200210010-00006","volume":"137","author":"MG Shlipak","year":"2002","unstructured":"Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB (2002) Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Am Int Med 137:555\u2013562","journal-title":"Am Int Med"},{"key":"79_CR79","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/mhj.2002.125512","volume":"144","author":"DN Reddan","year":"2002","unstructured":"Reddan DN (2002) Therapy for cardiovascular disease in patients with chronic kidney disease: appropriate cautions or the absence of data. Am Heart J 144:206\u2013207","journal-title":"Am Heart J"},{"key":"79_CR80","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.thromres.2007.03.006","volume":"121","author":"NR Bulatova","year":"2007","unstructured":"Bulatova NR, MF Yousef A, AbuRuz SM (2007) Antiplatelet therapy for primary and secondary prevention in Jordanian patients with diabetes mellitus. Thromb Res 121:43\u201350","journal-title":"Thromb Res"},{"key":"79_CR81","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccl.2004.11.002","volume":"23","author":"S Srikanth","year":"2005","unstructured":"Srikanth S, Deedwania P (2005) Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach. Cardiol Clin 23:193\u2013210","journal-title":"Cardiol Clin"},{"key":"79_CR82","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jacc.2006.04.026","volume":"47","author":"SC Smith","year":"2006","unstructured":"Smith SC, Allen J, Blair SN et al (2006) AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. JACC 47:2130\u20132139","journal-title":"JACC"},{"key":"79_CR83","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1160\/TH04-07-0453","volume":"93","author":"V Evangelista","year":"2005","unstructured":"Evangelista V, Totani L, Rotondo S, Lorenzet R, Tognoni G, De Berardis G, Nicolucci A (2005) Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 93:8\u201316","journal-title":"Thromb Haemost"},{"key":"79_CR84","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ahj.2004.08.030","volume":"149","author":"I Ikonomidis","year":"2005","unstructured":"Ikonomidis I, Lekakis J, Vamvakon G, Andreotti F, Nihoyannopulos P (2005) Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with coronary artery disease: effects of aspirin treatment. Am Heart J 149:832\u2013839","journal-title":"Am Heart J"},{"key":"79_CR85","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1160\/TH05-12-0808","volume":"95","author":"S Wong","year":"2006","unstructured":"Wong S, Morel- Kopp MC, Chen Q, Appleberg M, Ward CM, Lewis DR (2006) Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease. Thromb Haemost 95:1042\u20131043","journal-title":"Thromb Haemost"},{"key":"79_CR86","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.2337\/diacare.25.2007.S78","volume":"25(Suppl 1)","author":"American Diabetes Association","year":"2002","unstructured":"American Diabetes Association (2002) Clinical practice recommendations 2002, aspirin therapy in diabetes. Diabetes Care 25(Suppl 1):S78\u2013S79","journal-title":"Diabetes Care"},{"key":"79_CR87","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1160\/TH05-10-0653","volume":"95","author":"C Perneby","year":"2006","unstructured":"Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjemdahl P (2006) Dose and time-dependent antiplatelet effects of aspirin. Thromb Haemost 95:652\u2013658","journal-title":"Thromb Haemost"},{"key":"79_CR88","first-page":"517","volume":"119","author":"J Takahashi","year":"2007","unstructured":"Takahashi J, Ushida M, Komine R, Shimizu A, Uchida T, Ishihara H, Shibano T, Watanabe G, Ikeda Y, Murata M (2007) Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb. Res 119:517\u2013524","journal-title":"Res"},{"key":"79_CR89","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1345\/aph.1C101","volume":"37","author":"SU Nowak","year":"2003","unstructured":"Nowak SU, Jaber LA (2003) Aspirin dose for prevention of cardiovascular disease in diabetics. Am Pharmacother 37:116\u2013121","journal-title":"Am Pharmacother"},{"key":"79_CR90","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1111\/j.1538-7836.2005.01719.x","volume":"3","author":"JA Colwell","year":"2005","unstructured":"Colwell JA (2005) Is aspirin effective in diabetic patients? Yes. J Thromb Haemost 3:2612\u20132614","journal-title":"J Thromb Haemost"},{"key":"79_CR91","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1111\/j.1538-7836.2005.01720.x","volume":"3","author":"C Cimminiello","year":"2005","unstructured":"Cimminiello C (2005) Is aspirin effective in diabetic patients? No. J Thromb Haemost 3:2615\u20132616","journal-title":"J Thromb Haemost"},{"issue":"116","key":"79_CR92","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.thromres.2005.02.005","volume":"2005","author":"A Abaci","year":"2005","unstructured":"Abaci A, Yilmaz Y, Caliskan M, Bayram F, Cetin M, Unal A, Cetin S (2005) Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. Thromb Res 2005(116):465\u2013470","journal-title":"Thromb Res"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-008-0079-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-008-0079-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-008-0079-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T21:20:52Z","timestamp":1684704052000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-008-0079-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,2]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["79"],"URL":"https:\/\/doi.org\/10.1007\/s00592-008-0079-y","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,2]]}}}